What's new? Log in Free sign up

Exelixis (EXEL) News and press releases

Company Profile

News

From Benzinga Pro

8 Analysts Have This to Say About Exelixis

Analyst Ratings

JMP Securities Reiterates Market Outperform on Exelixis, Maintains $24 Price Target

News, Price Target, Reiteration, Analyst Ratings

JMP Securities analyst Silvan Tuerkcan reiterates Exelixis (NASDAQ:EXEL) with a Market Outperform and maintains $24 price target.

Piper Sandler Assumes Exelixis at Overweight, Announces Price Target of $28

News, Price Target, Initiation, Analyst Ratings

Piper Sandler analyst Joseph Catanzaro assumes Exelixis (NASDAQ:EXEL) with a Overweight rating and announces Price Target of $28.

Exelixis Q1 Adj. EPS $0.16 Beats $0.15 Estimate, Sales $408.79M Miss $424.10M Estimate

Exelixis (NASDAQ:EXEL) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.15 by 6.67 percent. This is a 38.46 percent decrease over earnings of $0.26 per share from the same

Exelixis: Q1 Earnings Insights

Earnings Scheduled For May 9, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million.

Amid Proxy Challenge From Farallon, Exelixis' Board Member Resigns

Biotech, News, Health Care, Management, General

Exelixis Inc's (NASDAQ: EXEL) board member Lance Willsey announced his resignation from the Board,

EF Hutton Reiterates Buy on Exelixis, Maintains $24 Price Target

News, Price Target, Reiteration, Analyst Ratings

EF Hutton analyst Michael King reiterates Exelixis (NASDAQ:EXEL) with a Buy and maintains $24 price target.

What 9 Analyst Ratings Have To Say About Exelixis

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on Exelixis, Lowers Price Target to $21

News, Price Target, Analyst Ratings

Morgan Stanley analyst Jefferson Harralson maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and lowers the price target from $22 to $21.

Facebook Turns To Generative AI For Help, FedEx Consolidates, UBS Executives Say Surprise Credit Suisse Deal 'Major Challenge:' Today's Top Stories

Biotech, Large Cap, M&A, News, Penny Stocks, Health Care, Hedge Funds, Top Stories, Markets, Tech, Media, General

Farallon Capital Might Undertake Proxy Fight Against Exelixis, Nominates Three Directors

Biotech, News, Health Care, Hedge Funds, General

Farallon Issues Letter To Exelixis Board of Directors Outlining Case For Change; Intends To Nominate 3 Director Candidates Who Will Bring New Perspectives To The Boardroom To Help Drive Change And Promote Accountability To Shareholders

News, Management

Believes the Company Must Focus R&D Efforts and Spending, Communicate a Coherent Strategy and Return Excess Capital to Shareholders in Order to Reverse Exelixis' Track Record of Underperformance Intends to

Analyst Ratings for Exelixis

Analyst Ratings

EF Hutton Reiterates Buy on Exelixis, Maintains $24 Price Target

News, Price Target, Reiteration, Analyst Ratings

EF Hutton analyst Michael King reiterates Exelixis (NASDAQ:EXEL) with a Buy and maintains $24 price target.

Press releases

From Benzinga Pro

Farallon Capital Management Comments on Election of All Three of Its Nominees to Exelixis' Board

Based on Preliminary Results, Farallon Director Candidates Tom Heyman, Dave Johnson and Bob Oliver Have Each Been Elected Expects Exelixis' Board to Welcome the New Directors and Embrace Fresh Perspectives to Help

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June

– Presentations to be webcast on www.exelixis.com – Exelixis, Inc. (NASDAQ:EXEL) today announced that members of the company's management team will participate in fireside chats at the following investor conferences

Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update

- Total Revenues of $408.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $363.4 million - - GAAP Diluted EPS of $0.12, Non-GAAP Diluted EPS of $0.16 - - Conference Call and Webcast Today at 5:00 PM

Farallon Capital Management Comments on Successful Campaign for Change at Exelixis

Pleased that Dave Johnson is Now Anticipated to Join Fellow Farallon Nominees Tom Heyman and Bob Oliver on Exelixis' Board of Directors Urges Shareholders to Send Clearest Message Possible That the Status Quo Cannot

Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors

Exelixis, Inc. (NASDAQ:EXEL) (the "Company") today announced that Lance Willsey, M.D. has informed the Board of Directors of his decision to resign from the Board, effective immediately. The Board recommends

Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023

– Presentations to be webcast on www.exelixis.com – Exelixis, Inc. (NASDAQ:EXEL) today announced that company management will participate in a fireside chat at the BofA Securities 2023 Healthcare Conference on

Exelixis Files Definitive Proxy Statement and Mails Letter to Shareholders

Urges Shareholders to Vote "FOR" All of Exelixis' 11 Recommended Director Nominees on the GOLD Proxy Card Exelixis, Inc. (NASDAQ:EXEL) (the "Company") today announced that it has filed its definitive proxy

Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its first quarter 2023 financial results will be released on Tuesday, May 9, 2023 after the

Exelixis Advances Board Refreshment Plan

Exelixis, Inc. (NASDAQ:EXEL) (the "Company") today announced that Carl Feldbaum, Esq. and Vincent Marchesi, M.D., Ph.D., two long-standing and valued members of the Board of Directors, will not stand for re-election at

Exelixis Reiterates Commitment to Shareholder Value Creation

Responds to Letter from Farallon Capital Management Exelixis, Inc. (NASDAQ:EXEL) (the "Company") today issued the following statement in response to the letter issued by Farallon Capital Management, L.L.C.

Exelixis Announces $550 Million Share Repurchase Program

Exelixis, Inc. (NASDAQ:EXEL) today announced that the company's Board of Directors has authorized the repurchase of up to $550 million of the company's common stock before the end of 2023. The timing and amount of any

Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit

- Presentation to be webcast on www.exelixis.com - Exelixis, Inc. (NASDAQ:EXEL) today announced that company management will provide a corporate overview at the 2023 Guggenheim Healthy Altitudes Summit on Thursday,

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.